Molecularly, BC is a heterogeneous disease characterized by hormone receptors (progesterone (PR) and estrogen (ER) receptors) activation, human epidermal growth factor receptor 2 (HER2) activation, and/or BRCA mutations. This evidence concerns the gene NR4A1 and breast cancer.